Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Download Free Report
Ann  Powell net worth and biography

Ann Powell Biography and Net Worth

Ann M. Powell is the global head of Human Resources and deeply committed to driving the company’s global capabilities in talent management, culture and organizational effectiveness while enabling an empowered workforce. She also currently serves as the executive sponsor of the Living Life Better company wellness program.

Ann partners across the company to foster an energized workforce and radically inclusive culture, where individuals are encouraged to exceed their potential and make innovative contributions for our patients and the global communities in which they live and work.

“At BMS, when we say we want people to bring their whole selves to work, we mean it. Courage, candor and inclusion fuel an innovative culture and, ultimately, a healthier future for all.  I’m inspired every day by the courage and passion of our workforce as we work together to make a difference in patients’ lives,” says Ann.

Ann’s expertise includes executive compensation, shaping culture, talent development, change management, team effectiveness, inclusion, diversity, learning design and delivery, talent attraction, labor relations, mergers and acquisitions, divestitures and start-ups.

With a career spanning both international and domestic assignments, Ann has worked within the oil/gas, chemical and pharmaceutical industries, including Chevron, Dow and Wyeth Pharmaceuticals. Prior to joining Bristol Myers Squibb in 2013, Ann was the chief human resources officer for Shire Pharmaceuticals.

Ann earned a bachelor’s degree from Iowa State University and a master’s degree in labor and industrial relations from the University of Minnesota.

What is Ann Powell's net worth?

The estimated net worth of Ann Powell is at least $1.62 million as of August 24th, 2023. Ms. Powell owns 27,868 shares of Bristol-Myers Squibb stock worth more than $1,620,106 as of September 28th. This net worth approximation does not reflect any other investments that Ms. Powell may own. Learn More about Ann Powell's net worth.

How old is Ann Powell?

Ms. Powell is currently 57 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. The oldest executive at Bristol-Myers Squibb is Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel, who is 62 years old. Learn More on Ann Powell's age.

How do I contact Ann Powell?

The corporate mailing address for Ms. Powell and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Ann Powell's contact information.

Has Ann Powell been buying or selling shares of Bristol-Myers Squibb?

In the last ninety days, Ann Powell has sold $1,101,642.50 of Bristol-Myers Squibb stock. Most recently, Ann Powell sold 17,986 shares of the business's stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a transaction totalling $1,101,642.50. Following the completion of the sale, the executive vice president now directly owns 27,868 shares of the company's stock, valued at $1,706,915. Learn More on Ann Powell's trading history.

Who are Bristol-Myers Squibb's active insiders?

Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.

Are insiders buying or selling shares of Bristol-Myers Squibb?

During the last year, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 382,446 shares worth more than $28,205,166.65. The most recent insider tranaction occured on August, 24th when EVP Ann Powell sold 17,986 shares worth more than $1,101,642.50. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.

Information on this page was last updated on 8/24/2023.

Ann Powell Insider Trading History at Bristol-Myers Squibb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2023Sell17,986$61.25$1,101,642.5027,868View SEC Filing Icon  
2/6/2023Sell11,183$74.69$835,258.2723,043View SEC Filing Icon  
11/9/2022Sell16,250$80.45$1,307,312.5034,226View SEC Filing Icon  
9/14/2022Sell25,000$70.75$1,768,750.0050,476View SEC Filing Icon  
See Full Table

Ann Powell Buying and Selling Activity at Bristol-Myers Squibb

This chart shows Ann Powell's buying and selling at Bristol-Myers Squibb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Read More

Today's Range

Now: $58.14
Low: $57.82
High: $58.42

50 Day Range

MA: $61.06
Low: $57.89
High: $64.74

2 Week Range

Now: $58.14
Low: $57.61
High: $81.43


8,264,692 shs

Average Volume

9,006,925 shs

Market Capitalization

$121.45 billion

P/E Ratio


Dividend Yield



Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Download Free Report